Basal cell carcinoma has low immunogenicity. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. Compromised antigen presentation ranks among the top ...

Liquid biopsy-based prediction of clinical benefit from immune checkpoint inhibitors in advanced biliary tract cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...

After months of shrinking scans, the tumors suddenly came roaring back. Oncologists have seen this pattern for years in patients on immunotherapy and targeted drugs: a dramatic initial response, then ...

An antigen is any substance that can trigger an immune response in the body. Antigens are typically proteins or polysaccharides that are recognized as foreign or potentially harmful by the immune ...

Combined epigenetic and immune checkpoint therapy altered the tumour microenvironment in platinum-resistant ovarian cancer.

It is well known that the biggest genetic risk factor for the autoimmune disease systemic lupus erythematosus (SLE) is major histocompatibility complex class II (MHC-II). What remains unclear is the ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Conjugate vaccines are composed of bacterial polysaccharide antigens covalently linked to protein carriers, enabling T cell-dependent immune responses that induce high-affinity antibodies and ...

1. Antigen preparation: Scientists can produce cancer vaccines against tumors by using the patient’s tumor as a source of antigen or by synthesizing peptides from tumor antigens. 2. Antigen delivery: ...